Does Rallies show Form 4 insider transactions for NXL?

Yes. Rallies tracks NXL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NXL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NXL. It does not provide personalized investment advice.

NXL (Nexalin Technology, Inc. Common Stock) Stock Analysis - Insider Trades

Nexalin Technology, Inc. Common Stock (NXL) is a publicly traded Healthcare sector company. As of May 19, 2026, NXL trades at $0.33 with a market cap of $7.05M and a P/E ratio of -0.67. NXL moved -0.28% today. Year to date, NXL is -44.30%; over the trailing twelve months it is -74.45%. Its 52-week range spans $0.31 to $4.49. Analyst consensus is buy with an average price target of $2.00. Rallies surfaces NXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NXL stock inside the company?

Recent NXL insider activity includes Shelton Carolyn Hamby bought 6.00K, Owens David bought 1.00K, Owens David bought 1.00K, Owens David bought 1.50K, and Owens David bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NXL Key Metrics

Key financial metrics for NXL
Metric	Value
Price	$0.33
Market Cap	$7.05M
P/E Ratio	-0.67
EPS	$-0.47
Dividend Yield	0.31%
52-Week High	$4.49
52-Week Low	$0.31
Volume	668.98K
Avg Volume	0
Revenue (TTM)	$275.58K
Net Income	$-8.33M
Gross Margin	81.99%

Recent NXL Insider Trades

Shelton Carolyn Hamby bought 6.00K (~$13.20K) on Mar 12, 2025.
Owens David bought 1.00K (~$3.10K) on Feb 4, 2025.
Owens David bought 1.00K (~$2.98K) on Feb 4, 2025.
Owens David bought 1.50K (~$4.05K) on Jan 28, 2025.
Owens David bought 1.00K (~$2.70K) on Jan 23, 2025.

Latest NXL News

Nexalin Acquires AI Platform for $1.3M to Support 160-Patient Trial — May 19, 2026
Nexalin Advances Pivotal 160-Participant HALO Clarity Insomnia Trial for De Novo FDA Pathway — Apr 22, 2026
Nexalin Plans Q2 2026 FDA Amendment After U.S. and China Alzheimer’s Strategy Meetings — Apr 15, 2026
Nexalin Study Shows 77.5 Hz, 15 mA DIFS Cuts Self-Injury and Depression — Apr 9, 2026

NXL Analyst Consensus

1 analysts cover NXL: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.00.

Common questions about NXL

Who is trading NXL stock inside the company?: Recent NXL insider activity includes Shelton Carolyn Hamby bought 6.00K, Owens David bought 1.00K, Owens David bought 1.00K, Owens David bought 1.50K, and Owens David bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NXL?: Yes. Rallies tracks NXL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NXL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NXL. It does not provide personalized investment advice.